TREATMENT WITH HUMAN MONOCLONAL ANTIBODY TO CONNECTIVE TISSUE GROWTH FACTOR (FG-

结缔组织生长因子 (FG-) 人单克隆抗体治疗

• 批准号: 7719299
• 负责人: HOWARD TRACHTMAN
• 金额: $ 0.64万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-22 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719299
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Hospitals; Hour; Infusion procedures; Institution; Patient observation; Patients; Pharmaceutical Preparations; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Visit; Week; connective tissue growth factor; human monoclonal antibodies; intravenous administration; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. FG-3019 treatment will be provided for 2 months and steady state PK will be conducted throughout the 2 month treatment period. The drug will be administered every 2 weeks for a total of 4 doses. FG-3019 will be administered as an intravenous infusion over 2 hours. The patient will remain in the hospital for 6 hours following the infusion for observation .The patient will be seen for a total of 6 visits over the 2 month treatment period.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 FG-3019治疗将提供2个月，并在整个2个月的治疗期间进行稳态PK。该药物将每 2 周给药一次，共 4 剂。 FG-3019 将在 2 小时内静脉输注。输注后患者将留在医院观察 6 小时。在 2 个月的治疗期间，患者将总共就诊 6 次。